{
    "clinical_study": {
        "@rank": "31712", 
        "arm_group": {
            "arm_group_label": "Paliperidone palmitate"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability of paliperidone\n      palmitate over a 9-week period for participants with schizophrenia in Korea."
        }, 
        "brief_title": "A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "detailed_description": {
            "textblock": "This is an open-label (all people know the identity of the intervention), multi-center,\n      prospective (look forward using observations collected following participant enrollment),\n      non-comparative, non-randomized (the study medication is not assigned by chance), study.\n      Safety and efficacy of paliperidone palmitate will be observed in Korean schizophrenic\n      participants for 25 weeks. Approximately 3000 participants will be observed in this study\n      and the study duration will be 25 weeks. Safety evaluations will include assessment of\n      adverse events, concomitant medications, physical examination, and psychiatric history."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants diagnosed with schizophrenia\n\n          -  Participants prescribed with paliperidone palmitate for acute or maintenance\n             treatment\n\n        Exclusion Criteria:\n\n          -  Participants who received paliperidone palmitate for other than the approved\n             indication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Participants with schizophrenia and prescribed with paliperidone palmitate for acute or\n        maintenance treatment."
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01819818", 
            "org_study_id": "CR100810", 
            "secondary_id": [
                "R092670SCH4007", 
                "PALM-KOR-PMS"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Paliperidone palmitate", 
            "description": "This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.", 
            "intervention_name": "No intervention", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "9-hydroxy-risperidone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Schizophrenia", 
            "Paliperidone palmitate", 
            "Invega", 
            "Sustenna", 
            "Korea"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "link": {
            "description": "To learn how to participate in this trial please click here.", 
            "url": "http://pam.sylogent.com/cr/CR100810"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Kyungki", 
                    "country": "Korea, Republic of"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Korea Post-Marketing Surveillance of Invega Sustenna", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:"
        }, 
        "overall_official": {
            "affiliation": "Janssen Korea, Ltd., Korea", 
            "last_name": "Janssen Korea, Ltd., Korea Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Korea Food and Drug Administration", 
                "Republic of Korea: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with adverse events up to Week 9", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Week 9"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01819818"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of participants with adverse events up to Week 25", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 25"
            }, 
            {
                "description": "The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to \"Normal, not at all ill\" and a rating of 7 is equivalent to \"Among the most extremely ill participants\". Higher scores indicate worsening.", 
                "measure": "Change from baseline in Clinical Global impression-Severity (CGI-S) scale scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1), Week 5, Week 9, Week 13, Week 17, Week 21, and Week 25"
            }, 
            {
                "description": "This PSP assesses the degree of a participants dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (i, absent to vi, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; =< 30, functioning so poorly as to require intensive supervision.", 
                "measure": "Change from baseline in Personal and Social Performance (PSP) scale scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1), Week 5, Week 9, Week 13, Week 17, Week 21, and Week 25"
            }
        ], 
        "source": "Janssen Korea, Ltd., Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Korea, Ltd., Korea", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}